Agios Pharmaceuticals (AGIO) Free Cash Flow (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Free Cash Flow of -$119.7 million for Q1 2026, down 24.47% on a QoQ basis from -$96.2 million in Q4 2025, and down 6.62% year-over-year from -$128.2 million in Q1 2025.
Agios Pharmaceuticals (AGIO) Free Cash Flow (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$119.7 million for Q1 2026.
- Quarterly Free Cash Flow fell 6.62% year-over-year to -$119.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$380.7 million (up 5.75% YoY) and the FY2025 annual result came in at -$373.3 million, up 4.67% from the prior year.
- Free Cash Flow was -$119.7 million for Q1 2026 at Agios Pharmaceuticals, down from -$96.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$61.6 million in Q4 2022 and bottomed at -$134.8 million in Q4 2024.
- A 5-year average of -$87.7 million and a median of -$84.2 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 53.92% — and 2024, when it plunged 83.46%.
- Agios Pharmaceuticals' Free Cash Flow stood at -$61.6 million in 2022, then dropped by 19.37% to -$73.5 million in 2023, then plunged by 83.46% to -$134.8 million in 2024, then rose by 28.66% to -$96.2 million in 2025, then dropped by 24.47% to -$119.7 million in 2026.
- Business Quant data shows AGIO's Free Cash Flow at -$119.7 million in Q1 2026, -$96.2 million in Q4 2025, and -$86.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -119.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.69 Mn |
| Mar 31, 2026 | -119.69 Mn |
| Dec 31, 2025 | -96.16 Mn |
| Dec 31, 2025 | -96.16 Mn |
| Sep 30, 2025 | -86.85 Mn |
| Sep 30, 2025 | -86.85 Mn |
| Jun 30, 2025 | -78.00 Mn |
| Jun 30, 2025 | -78.00 Mn |
| Mar 31, 2025 | -112.26 Mn |
| Mar 31, 2025 | -112.26 Mn |
| Dec 31, 2024 | -134.79 Mn |
| Dec 31, 2024 | -134.79 Mn |
| Sep 30, 2024 | -84.24 Mn |
| Sep 30, 2024 | -84.24 Mn |
| Jun 30, 2024 | -72.63 Mn |
| Jun 30, 2024 | -72.63 Mn |
| Mar 31, 2024 | -99.87 Mn |
| Mar 31, 2024 | -99.87 Mn |
| Dec 31, 2023 | -73.47 Mn |
| Dec 31, 2023 | -73.47 Mn |